Triple-Drug Fixed‑Dose Combo Archives

Showing all 5 results

Duovir‑E Kit (Lamivudine 150 mg + Zidovudine 300 mg + Efavirenz 600 mg)
0 out of 5
Price range: $66 through $146
Duovir‑E Kit (Lamivudine 150 mg + Zidovudine 300 mg + Efavirenz 600 mg Tablets) is a fixed-dose combination regimen used in HIV‑1 treatment. It merges two nucleoside reverse transcriptase inhibitors (lamivudine and zidovudine) with a non-nucleoside reverse transcriptase inhibitor (efavirenz) for potent viral suppression, immune restoration, and simplified daily dosing under clinical supervision.

Select options This product has multiple variants. The options may be chosen on the product page
Duovir‑N 150 mg/200 mg/300 mg
0 out of 5
Price range: $75 through $200
Duovir‑N 150 mg/200 mg/300 mg (Lamivudine + Zidovudine + Nevirapine Tablets) is a fixed‑dose combination tablet used in HIV‑1 treatment. This regimen combines lamivudine and zidovudine, two NRTIs, with nevirapine, an NNRTI, to reduce viral replication and restore immune function. Administered once or twice daily under clinical supervision, it supports adherence and simplifies long-term antiretroviral therapy.

Select options This product has multiple variants. The options may be chosen on the product page
Trioday 300 mg/300 mg/600 mg (Lamivudine + Tenofovir + Efavirenz)
0 out of 5
Price range: $190 through $580
Trioday 300 mg/300 mg/600 mg (Lamivudine + Tenofovir + Efavirenz Tablets) is a fixed-dose combination tablet used in HIV‑1 treatment. It merges two nucleoside reverse transcriptase inhibitors (lamivudine and tenofovir) with a non-nucleoside reverse transcriptase inhibitor (efavirenz) for comprehensive viral suppression and immune recovery. Designed for once-daily dosing, Trioday simplifies ART regimens under clinical guidance.

Select options This product has multiple variants. The options may be chosen on the product page
Triomune (Stavudine + Lamivudine + Nevirapine)
0 out of 5
Price range: $85 through $265
Triomune (Stavudine + Lamivudine + Nevirapine Tablets) is a fixed-dose combination used in HIV‑1 treatment, integrating two nucleoside reverse transcriptase inhibitors (stavudine and lamivudine) with a non‑nucleoside reverse transcriptase inhibitor (nevirapine). This once‑daily tablet supports robust viral suppression, CD4 recovery, and treatment adherence in clinician-supervised regimens.

Select options This product has multiple variants. The options may be chosen on the product page
Viraday 300 mg/200 mg/600 mg (Tenofovir + Emtricitabine + Efavirenz)
0 out of 5
Price range: $140 through $410
Viraday (300 mg Tenofovir + 200 mg Emtricitabine + 600 mg Efavirenz Tablets) is an integrated single-tablet regimen for HIV‑1 treatment. This triple-drug therapy combines two NRTIs (tenofovir, emtricitabine) with an NNRTI (efavirenz) to achieve robust viral suppression, immune recovery, and adherence support via once-daily dosing under physician supervision.

Select options This product has multiple variants. The options may be chosen on the product page